Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
EyeGate says first patient dosed in Phase 2 POC study of PP-001 » 06:56
06/14/21
06/14
06:56
06/14/21
06:56
EYEG

EyeGate

$4.42 /

-0.05 (-1.12%)

EyeGate Pharmaceuticals…

EyeGate Pharmaceuticals announced the first patient dosed in phase II proof-of-concept study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase and is first-in-class for ophthalmology indications. The randomized, double-masked, placebo-controlled POC study will be conducted at a site in Vienna, Austria and is designed to evaluate the safety, tolerability and efficacy of PP-001 in patients with ocular surface inflammation due to dry eye disease. A total of 21 patients will receive 0.15% of PP-001 or placebo for 12 days. The outcome of this study will guide the U.S. clinical development program for dry eye disease following the filing of the IND, which is expected in Q4.

ShowHide Related Items >><<
EYEG EyeGate
$4.42 /

-0.05 (-1.12%)

EYEG EyeGate
$4.42 /

-0.05 (-1.12%)

05/18/21 Alliance Global Partners
EyeGate price target raised to $10.75 from $10.25 at Alliance Global Partners
03/31/21 Alliance Global Partners
EyeGate price target lowered to $10.25 from $16.75 at Alliance Global
02/04/21 Alliance Global Partners
EyeGate price target raised to $16.75 from $15.50 at Alliance Global Partners
12/22/20 Alliance Global Partners
EyeGate price target raised to $15.50 from $9.50 at Alliance Global Partners
Recommendations
EyeGate price target raised to $10.75 from $10.25 at Alliance Global Partners » 10:33
05/18/21
05/18
10:33
05/18/21
10:33
EYEG

EyeGate

$4.11 /

+0.36 (+9.60%)

Alliance Global Partners…

Alliance Global Partners analyst Ben Haynor raised the firm's price target on EyeGate Pharmaceuticals to $10.75 from $10.25 and reiterates a Buy rating on the shares. The company last week confirmed it would pursue regulatory approval of EyeGate Ocular Bandage Gel as a drug through the FDA's Center for Drug Evaluation and Research division, Haynor tells investors in a research note. Although moving Ocular Bandage Gel to the drug approval route will lengthen its timeline to approval, classification as a drug will allow for Medicare Part D reimbursement, which is "crucial" given that roughly half of dry eye disease patients are of Medicare age, says the analyst.

ShowHide Related Items >><<
EYEG EyeGate
$4.11 /

+0.36 (+9.60%)

EYEG EyeGate
$4.11 /

+0.36 (+9.60%)

03/31/21 Alliance Global Partners
EyeGate price target lowered to $10.25 from $16.75 at Alliance Global
02/04/21 Alliance Global Partners
EyeGate price target raised to $16.75 from $15.50 at Alliance Global Partners
12/22/20 Alliance Global Partners
EyeGate price target raised to $15.50 from $9.50 at Alliance Global Partners
12/22/20 H.C. Wainwright
EyeGate price target raised to $14 from $10 at H.C. Wainwright
Over a quarter ago
Syndicate
EyeGate files to sell 3.93M shares of common stock for holders  16:52
04/16/21
04/16
16:52
04/16/21
16:52
EYEG

EyeGate

$4.26 /

+0.06 (+1.43%)

 
ShowHide Related Items >><<
EYEG EyeGate
$4.26 /

+0.06 (+1.43%)

EYEG EyeGate
$4.26 /

+0.06 (+1.43%)

03/31/21 Alliance Global Partners
EyeGate price target lowered to $10.25 from $16.75 at Alliance Global
02/04/21 Alliance Global Partners
EyeGate price target raised to $16.75 from $15.50 at Alliance Global Partners
12/22/20 Alliance Global Partners
EyeGate price target raised to $15.50 from $9.50 at Alliance Global Partners
12/22/20 H.C. Wainwright
EyeGate price target raised to $14 from $10 at H.C. Wainwright
Recommendations
EyeGate price target lowered to $10.25 from $16.75 at Alliance Global » 09:52
03/31/21
03/31
09:52
03/31/21
09:52
EYEG

EyeGate

$4.73 /

+0.085 (+1.83%)

Alliance Global Partners…

Alliance Global Partners analyst Ben Haynor lowered the firm's price target on EyeGate Pharmaceuticals to $10.25 from $16.75 and reiterates a Buy rating on the shares post the company's Q4 results. The analyst adjusted his operating expensive model pending greater clarity on the regulatory paths and indications EyeGate shall choose with OBG and PP-001.

ShowHide Related Items >><<
EYEG EyeGate
$4.73 /

+0.085 (+1.83%)

EYEG EyeGate
$4.73 /

+0.085 (+1.83%)

02/04/21 Alliance Global Partners
EyeGate price target raised to $16.75 from $15.50 at Alliance Global Partners
12/22/20 Alliance Global Partners
EyeGate price target raised to $15.50 from $9.50 at Alliance Global Partners
12/22/20 H.C. Wainwright
EyeGate price target raised to $14 from $10 at H.C. Wainwright
07/21/20 Alliance Global Partners
EyeGate initiated with a Buy at Alliance Global Partners
Recommendations
EyeGate price target raised to $16.75 from $15.50 at Alliance Global Partners » 08:58
02/04/21
02/04
08:58
02/04/21
08:58
EYEG

EyeGate

$6.55 /

+0.25 (+3.97%)

Alliance Global Partners…

Alliance Global Partners analyst Ben Haynor raised the firm's price target on EyeGate Pharmaceuticals to $16.75 from $15.50 and reiterates a Buy rating on the shares after speaking with management. The analyst believes the market for a highly potent, highly specific dihydroorotate dehydrogenase inhibitor is "substantial." He sees EyeGate's PP-001 as having the characteristics that would enable it to successfully target a larger list of indications than their initial ophthalmology targets.

ShowHide Related Items >><<
EYEG EyeGate
$6.55 /

+0.25 (+3.97%)

EYEG EyeGate
$6.55 /

+0.25 (+3.97%)

12/22/20 Alliance Global Partners
EyeGate price target raised to $15.50 from $9.50 at Alliance Global Partners
12/22/20 H.C. Wainwright
EyeGate price target raised to $14 from $10 at H.C. Wainwright
07/21/20 Alliance Global Partners
EyeGate initiated with a Buy at Alliance Global Partners
Hot Stocks
EyeGate appoints Franz Obermayr as Acting CEO » 06:57
02/01/21
02/01
06:57
02/01/21
06:57
EYEG

EyeGate

$6.36 /

+0.09 (+1.44%)

EyeGate Pharmaceuticals…

EyeGate Pharmaceuticals announced that Franz Obermayr, Managing Director and former CEO of recently acquired Panoptes Pharma, was appointed as Acting CEO and will transition from his current role at EyeGate as EVP Clinical Development, effective February 1. As part of this transition, Stephen From will be elevated from his current role as President and CEO to providing strategic support as Executive Chairman. Obermayr was previously the Co-Founder and CEO of Panoptes Pharma, a privately held biotech company, which was acquired by EyeGate in 2020. Before joining the management team at EyeGate, Obermayr had a major role in the development, clinical milestones and regulatory strategic efforts for the Company's transformative asset, PP-001, which has two novel formulations. Prior to Panoptes, Obermayr was Head of Clinical Development at Nabriva Therapeutics AG, where he was responsible for all clinical programs.

ShowHide Related Items >><<
EYEG EyeGate
$6.36 /

+0.09 (+1.44%)

EYEG EyeGate
$6.36 /

+0.09 (+1.44%)

12/22/20 Alliance Global Partners
EyeGate price target raised to $15.50 from $9.50 at Alliance Global Partners
12/22/20 H.C. Wainwright
EyeGate price target raised to $14 from $10 at H.C. Wainwright
07/21/20 Alliance Global Partners
EyeGate initiated with a Buy at Alliance Global Partners
Syndicate
EyeGate raises $8M in a private placement » 07:02
01/06/21
01/06
07:02
01/06/21
07:02
EYEG

EyeGate

$5.05 /

+0.05 (+1.00%)

EyeGate announced that it…

EyeGate announced that it has entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of approximately $8.0 million. The Warrants have an exercise price of $5.225 per share, will become exercisable six months following the closing, and have a five-year term.

ShowHide Related Items >><<
EYEG EyeGate
$5.05 /

+0.05 (+1.00%)

EYEG EyeGate
$5.05 /

+0.05 (+1.00%)

12/22/20 Alliance Global Partners
EyeGate price target raised to $15.50 from $9.50 at Alliance Global Partners
12/22/20 H.C. Wainwright
EyeGate price target raised to $14 from $10 at H.C. Wainwright
07/21/20 Alliance Global Partners
EyeGate initiated with a Buy at Alliance Global Partners
Recommendations
EyeGate price target raised to $15.50 from $9.50 at Alliance Global Partners » 07:15
12/22/20
12/22
07:15
12/22/20
07:15
EYEG

EyeGate

$5.20 /

+1.6 (+44.44%)

, SNY

Sanofi

$47.08 /

-1.07 (-2.22%)

Alliance Global Partners…

Alliance Global Partners analyst Ben Haynor raised the firm's price target on EyeGate (EYEG) to $15.50 from $9.50 and keeps a Buy rating on the shares after the company announced the acquisition of Panoptes Pharma, which is focused on small molecule therapies in severe eye diseases with high unmet medical need. Panoptes' lead asset, PP-001, is a small molecule inhibitor of dihydroorotate dehydrogenase and "DHODH inhibition appears to us a promising avenue in ophthalmology," said Haynor. He notes that Sanofi (SNY) has gained FDA approval of two "first-generation" DHODH inhibitors and that PP-001 is considered a "third-generation" DHODH inhibitor which may have both high specificity and potency.

ShowHide Related Items >><<
SNY Sanofi
$47.08 /

-1.07 (-2.22%)

EYEG EyeGate
$5.20 /

+1.6 (+44.44%)

EYEG EyeGate
$5.20 /

+1.6 (+44.44%)

12/22/20 H.C. Wainwright
EyeGate price target raised to $14 from $10 at H.C. Wainwright
07/21/20 Alliance Global Partners
EyeGate initiated with a Buy at Alliance Global Partners
SNY Sanofi
$47.08 /

-1.07 (-2.22%)

11/30/20 Morgan Stanley
AbbVie price target raised to $120 from $108 at Morgan Stanley
11/03/20 Morgan Stanley
Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley
10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
SNY Sanofi
$47.08 /

-1.07 (-2.22%)

SNY Sanofi
$47.08 /

-1.07 (-2.22%)

SNY Sanofi
$47.08 /

-1.07 (-2.22%)

Recommendations
EyeGate price target raised to $14 from $10 at H.C. Wainwright » 06:10
12/22/20
12/22
06:10
12/22/20
06:10
EYEG

EyeGate

$5.20 /

+1.6 (+44.44%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen raised the firm's price target on EyeGate Pharmaceuticals to $14 from $10 and reiterates a Buy rating on the shares. The acquisition of Panoptes Pharma expands the company's pipeline with a potentially best-in-class DHODH inhibitor, Chen tells investors in a research note. This acquisition has "significantly expanded and enriched" EyeGate's pipeline, with multiple programs spanning indications both within and beyond ophthalmology, says the analyst.

ShowHide Related Items >><<
EYEG EyeGate
$5.20 /

+1.6 (+44.44%)

EYEG EyeGate
$5.20 /

+1.6 (+44.44%)

07/21/20 Alliance Global Partners
EyeGate initiated with a Buy at Alliance Global Partners
Hot Stocks
EyeGate acquires Panoptes Pharma for $4M in stock, cash » 06:58
12/21/20
12/21
06:58
12/21/20
06:58
EYEG

EyeGate

$3.60 /

-0.01 (-0.28%)

EyeGate Pharmaceuticals…

EyeGate Pharmaceuticals announced the acquisition of Panoptes Pharma, a privately-held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need. The acquisition transforms EyeGate's pipeline with the addition of PP-001, a next-generation, non-steroidal, immuno-modulatory, small molecule inhibitor of Dihydroorotate Dehydrogenase with potential best-in-class picomolar potency. Under the terms of the agreement, Panoptes will become a wholly owned subsidiary of EyeGate. The consideration from EyeGate is $4M at close consisting of EyeGate common stock, EyeGate preferred stock and cash. Additionally, $1.5M in consideration is held back and will be issued in EyeGate preferred stock after a period of 18 months, subject to adjustments for post-closing working capital or indemnification obligations. The transaction also includes two cash or share earn-out provisions, each calling for an additional payment of up to $4.75M contingent upon 1) the enrollment and randomization of a first patient into the first Phase III pivotal study of any Panoptes ophthalmic product with the FDA, and 2) an approval of a New Drug Application by the FDA with respect to any Panoptes ophthalmic product.

ShowHide Related Items >><<
EYEG EyeGate
$3.60 /

-0.01 (-0.28%)

EYEG EyeGate
$3.60 /

-0.01 (-0.28%)

07/21/20 Alliance Global Partners
EyeGate initiated with a Buy at Alliance Global Partners

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.